Pancreas disorder
diseaseOn this page
Also known as disease of pancreasdisease or disorder of pancreasdisease, pancreaticdiseases, pancreaticdisorder of pancreaspancreas diseasepancreas disease or disorderpancreatic diseasepancreatic disorder
Summary
Pancreas disorder (MONDO:0002356) is a disease (an umbrella term covering 14 Mondo subtypes) with 13 GWAS associations across 25 studies and 137 clinical trials. Top therapeutic interventions include alfentanil, cefoxitin, and dextrose. A subtype of digestive system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 14 Mondo subtypes
- GWAS associations: 13
- Clinical trials: 137
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | pancreas disorder |
| Mondo ID | MONDO:0002356 |
| EFO | EFO:0009605 |
| MeSH | D010182 |
| DOID | DOID:26 |
| ICD-10-CM | K86.9 |
| ICD-11 | 1726554290 |
| NCIT | C26842 |
| SNOMED CT | 3855007 |
| UMLS | C0030286 |
| MedGen | 14583 |
| Anatomy (UBERON) | UBERON:0001264 |
| Is cancer (heuristic) | no |
Also known as: disease of pancreas · disease or disorder of pancreas · disease, pancreatic · diseases, pancreatic · disorder of pancreas · pancreas disease · pancreas disease or disorder · pancreatic disease · pancreatic disorder
Data availability: 13 GWAS associations (25 studies).
Disease family
This is a subtype of digestive system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › pancreas disorder
Related subtypes (30): benign digestive system neoplasm, autoimmune disorder of gastrointestinal tract, gastrointestinal mucositis, diarrheal disease, hepatobiliary disorder, digestive system cancer, peptic ulcer disease, stomach disorder, intestinal disorder, Meckel diverticulum, Cronkhite-Canada syndrome, diverticulosis, small-intestinal, diverticulosis of bowel, hernia, and retinal detachment, congenital enteropathy due to enteropeptidase deficiency, hereditary mixed polyposis syndrome, caudal duplication, Moyamoya disease with early-onset achalasia, hyperplastic polyposis syndrome, thoraco-abdominal enteric duplication, digestive duplication, juvenile polyposis syndrome, umbilical cord ulceration-intestinal atresia syndrome, growth retardation-mild developmental delay-chronic hepatitis syndrome, common mesentery, neoplasm of oropharynx, gastrointestinal polyp, digestive system neuroendocrine neoplasm, digestive system infectious disorder, upper digestive tract disorder, congenital peritoneal encapsulation
Subtypes (14): pancreatic steatorrhea, pancreatic mucinous ductal ectasia, exocrine pancreatic insufficiency, endocrine pancreas disorder, pancreatitis, annular pancreas, pancreatic triacylglycerol lipase deficiency, follicular cholangitis and pancreatitis, congenital pancreatic cyst, recurrent acute pancreatitis, accessory pancreas, pancreatic neoplasm, acinar cystic transformation of the pancreas, lymphoepithelial cyst of the pancreas
Genetics & variants
GWAS landscape
13 GWAS associations across 25 studies. Top hits map to 3 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| chr6:32659703 | 9e-39 | A | 0.29 | |
| rs113993960 | 3e-32 | CFTR | ? | 3 |
| rs679574 | 3e-15 | FUT2 | C | 0.09 |
| rs148911734 | 2e-12 | SPINK1 - SCGB3A2 | C | 0.39 |
| rs2855972 | 3e-12 | PRSS1 - PRSS2 | C | 0.08 |
| rs3741297 | 3e-10 | ZPR1 | ? | |
| chr10:112998590 | 1e-09 | T | 0.14 | |
| chr13:113734735 | 4e-09 | C | 3.84 | |
| chr20:63126477 | 1e-08 | C | 3.74 | |
| chr9:74432423 | 2e-08 | G | 2.48 | |
| chr4:163624309 | 3e-08 | T | 1.45 | |
| chr11:116383575 | 4e-08 | T | 0.13 | |
| chrX:64626738 | 5e-08 | C | 1.75 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90478483 | Verma A | 2024 | 12,564 | 431,876 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90478482 | Verma A | 2024 | 4,616 | 115,057 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90480360 | Verma A | 2024 | 4,616 | 115,057 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90473182 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 4,573 | 453,867 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90667895 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 4,573 | 453,867 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90473885 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 3,632 | 454,808 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90436394 | Zhou W | 2018 | 2,690 | 406,271 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
| GCST90651267 | Liu TY | 2025 | 2,151 | 234,326 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90079750 | Backman JD | 2021 | 1,620 | 385,084 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90083736 | Backman JD | 2021 | 1,620 | 385,084 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 1 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 12 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 3 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 1 |
| unknown | 9 |
Functional consequences
| Consequence | Count |
|---|---|
| unknown | 8 |
| intron_variant | 2 |
| intergenic_variant | 2 |
| inframe_insertion | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| chr6:32659703 | 9e-39 | Tier 4: intronic/intergenic | ||||||
| rs113993960 | 7 | 117559591 | ATCT>A,ATCTTCT | 0.05 | inframe_insertion | CFTR | 3e-32 | Tier 1: coding |
| rs679574 | 19 | 48702851 | C>A,G | 0.474 | intron_variant | FUT2 | 3e-15 | Tier 4: intronic/intergenic |
| rs148911734 | 5 | 147838808 | C>A,T | 0.008 | intergenic_variant | SPINK1 - SCGB3A2 | 2e-12 | Tier 4: intronic/intergenic |
| rs2855972 | 7 | 142756070 | C>A,G,T | 0.459 | intergenic_variant | PRSS1 - PRSS2 | 3e-12 | Tier 4: intronic/intergenic |
| rs3741297 | 11 | 116786951 | C>T | intron_variant | ZPR1 | 3e-10 | Tier 4: intronic/intergenic | |
| chr10:112998590 | 1e-09 | Tier 4: intronic/intergenic | ||||||
| chr13:113734735 | 4e-09 | Tier 4: intronic/intergenic | ||||||
| chr20:63126477 | 1e-08 | Tier 4: intronic/intergenic | ||||||
| chr9:74432423 | 2e-08 | Tier 4: intronic/intergenic | ||||||
| chr4:163624309 | 3e-08 | Tier 4: intronic/intergenic | ||||||
| chr11:116383575 | 4e-08 | Tier 4: intronic/intergenic | ||||||
| chrX:64626738 | 5e-08 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 137.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 114 |
| PHASE4 | 7 |
| PHASE3 | 6 |
| PHASE2 | 6 |
| PHASE2/PHASE3 | 2 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07024199 | PHASE4 | RECRUITING | Comparison of the Effectiveness of Paracetamol With Ibuprofen or Paracetamol With Metamizole in Treating Pain in Acute Pancreatitis in Children |
| NCT00526331 | PHASE4 | COMPLETED | Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy |
| NCT00661648 | PHASE4 | UNKNOWN | Effect of an Artificial Pancreas in Patients Undergoing Pancreatic Resection |
| NCT01350037 | PHASE4 | COMPLETED | Alfentanil Versus Remifentanil in Patient-controlled Sedation During Endoscopic Retrograde Cholangiopancreatography (ERCP) |
| NCT02092519 | PHASE4 | COMPLETED | RCT: Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses |
| NCT03198871 | PHASE4 | COMPLETED | IV Acetaminophen for Post-Operative Pain Management in Enhanced Recovery After Surgery (ERAS) Population |
| NCT05832047 | PHASE4 | COMPLETED | Aggressive Hydration With Lactated Ringer’s Solution Versus Plasma Solution for the Prevention of Post ERCP Pancreatitis |
| NCT06861010 | PHASE3 | RECRUITING | Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis |
| NCT00731198 | PHASE3 | COMPLETED | Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP) |
| NCT00975702 | PHASE3 | COMPLETED | Remote Ischemic Preconditioning In Abdominal Organ Transplantation |
| NCT01087801 | PHASE3 | COMPLETED | A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers |
| NCT01964430 | PHASE3 | COMPLETED | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the Apact Study) |
| NCT03269994 | PHASE3 | COMPLETED | Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy? |
| NCT04021264 | PHASE2/PHASE3 | WITHDRAWN | The Impact of an Epidural Anesthetic on the Consumption of Sevoflurane in Major Abdominal Surgery |
| NCT04329039 | PHASE2/PHASE3 | SUSPENDED | Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics |
| NCT07559175 | PHASE2 | NOT_YET_RECRUITING | A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency. |
| NCT00040131 | PHASE2 | TERMINATED | Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED) |
| NCT00902291 | PHASE2 | COMPLETED | A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer |
| NCT01608711 | PHASE2 | COMPLETED | A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002 |
| NCT03410914 | PHASE2 | COMPLETED | Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy |
| NCT03535727 | PHASE1/PHASE2 | COMPLETED | A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer |
| NCT03717298 | PHASE2 | COMPLETED | Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma |
| NCT01832116 | PHASE1 | COMPLETED | 89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients |
| NCT00830557 | Not specified | RECRUITING | Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders |
| NCT02471170 | Not specified | ENROLLING_BY_INVITATION | Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases |
| NCT03260842 | Not specified | RECRUITING | Bio-Repository of High Risk Cohorts for the Early Detection of Pancreas Cancer |
| NCT03334708 | Not specified | RECRUITING | A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma |
| NCT03807687 | Not specified | RECRUITING | Registry of Pancreatic Disease |
| NCT04259580 | Not specified | RECRUITING | Calgary Registry for Advanced and Therapeutic Endoscopy |
| NCT04291651 | Not specified | RECRUITING | UCSF PANC Cyst Registry |
| NCT04493632 | Not specified | RECRUITING | OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry. |
| NCT04556019 | Not specified | RECRUITING | Results of Surgical Treatment of the Hepatobiliopancreatic Surgical Unit |
| NCT04760847 | Not specified | NOT_YET_RECRUITING | Intermittent Fasting for Pancreatitis |
| NCT04949282 | Not specified | RECRUITING | Spanish Series of Patients Treated With the Radionuclide Lutetium177 |
| NCT05014347 | Not specified | ACTIVE_NOT_RECRUITING | Patient Reported Experience in Endoscopic Ultrasound |
| NCT05155878 | Not specified | RECRUITING | Prognostic Factors in Periampullary Tumors and Cysts |
| NCT05193162 | Not specified | RECRUITING | Retrospective Study on Microbial Diversity in Paraffin Tissue of Pancreatic Diseases |
| NCT05356039 | Not specified | RECRUITING | Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer |
| NCT05474417 | Not specified | RECRUITING | The Effects of the CF Carrier State on the Kidneys and Pancreas |
| NCT05714111 | Not specified | RECRUITING | Radiology Registry on Pancreatic Malignancies |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ALFENTANIL | 4 | 1 |
| CEFOXITIN | 4 | 1 |
| DEXTROSE | 4 | 1 |
| FIBRINOGEN I 125 | 4 | 1 |
| PANCRELIPASE | 4 | 1 |
| PIPERACILLIN | 4 | 1 |
| REMIFENTANIL | 4 | 1 |
| SECRETIN SYNTHETIC HUMAN | 4 | 1 |
| SOMATOSTATIN | 3 | 1 |
| MK-4721 | 2 | 2 |
| ALBACONAZOLE | 2 | 1 |
| INTERLEUKIN-10 | 2 | 1 |
| CHEMBL5483040 | 0 | 1 |
| CHEMBL423707 | 0 | 1 |
| SCEPTRIN | 0 | 1 |